We currently have two platforms in our drug development pipeline. We began a Phase 2 clinical study with PVSRIPO in glioblastoma multiforme (GBM) in mid-2017 and expect to initiate pre-clinical studies in multiple other solid tumors. Initial pre-clinical and clinical studies indicate that solid tumor types accessible for intratumoral injection may also be optimal targets for PVSRIPO, including melanoma and breast, prostate, colorectal, lung, pancreatic, ovarian and renal cancers. We expect to initiate a Phase 1 combination trial in melanoma in 2017. As funding allows, we plan to initiate Phase 1 trials in breast and prostate cancer.
Our ADC conjugate, D2C7-IT, is under evaluation in a dose escalation Phase 1 study in 24 recurrent GBM patients. It has been well-tolerated in 16 patients studied so far. We also have ADCs for additional tumors in pre-clinical development. Using different cytotoxic agents and linkers may lead to additional pipeline therapeutics for Istari Oncology. A wide variety of tumor types can be targeted by ADCs.
Learn more about our ongoing clinical studies with PVSRIPO and ADC.